We are live on ! Find out more
BC

Birchview Capital Portfolio holdings

AUM $176M
1-Year Est. Return 95.04%
This Fund
S&P 500
This Quarter Est. Return
+34.93%
1 Year Est. Return
+95.04%
3 Year Est. Return
+233.14%
5 Year Est. Return
+280.2%
10 Year Est. Return
+1,023.63%
AUM
$132M
AUM Growth
+$31.8M
Cap. Flow
+$10.8M
Cap. Flow %
8.18%
Top 10 Hldgs %
55.55%
Holding
79
New
8
Increased
18
Reduced
14
Closed
10

Top Buys

Rank Stock Value
1
KLAC icon
KLA
KLAC
+$5.63M
2
CMPX icon
Compass Therapeutics
CMPX
+$2.76M
3
FOLD
Amicus Therapeutics
FOLD
+$1.6M
4
BCYC
Bicycle Therapeutics
BCYC
+$1.16M
5
GPCR icon
Structure Therapeutics
GPCR
+$837K

Top Sells

Rank Stock Value
1
TVTX icon
Travere Therapeutics
TVTX
+$1.13M
2
ELUT icon
Elutia
ELUT
+$830K
3
HROW icon
Harrow
HROW
+$753K
4
AXGN icon
Axogen
AXGN
+$608K
5
XNCR icon
Xencor
XNCR
+$550K

Sector Composition

Rank Sector Weight
1 Healthcare 76.79%
2 Technology 17.82%
3 Energy 4.7%
4 Materials 0.53%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
KLAC icon
1
KLA
KLAC
$278B
$23.6M 17.82%
218,830
+60,350
+38% +$5.63M
BMY icon
2
Bristol-Myers Squibb
BMY
$124B
$14.3M 10.79%
316,842
-6,516
-2% -$304K
CORT icon
3
Corcept Therapeutics
CORT
$9.72B
$5.58M 4.22%
67,200
– –
PRTA icon
4
Prothena Corp
PRTA
$453M
$5.36M 4.05%
549,019
+98,000
+22% +$753K
STOK icon
5
Stoke Therapeutics
STOK
$1.81B
$4.93M 3.73%
210,000
– –
QURE icon
6
uniQure
QURE
$2.77B
$4.6M 3.47%
78,728
-19,969
-20% -$363K
OVV icon
7
Ovintiv
OVV
$16.2B
$4.34M 3.28%
107,500
– –
NBIX icon
8
Neurocrine Biosciences
NBIX
$17.2B
$4.03M 3.04%
28,690
-2,250
-7% -$305K
ACAD icon
9
Acadia Pharmaceuticals
ACAD
$4.38B
$3.65M 2.76%
171,000
-16,800
-9% -$397K
PTGX icon
10
Protagonist Therapeutics
PTGX
$9.06B
$3.19M 2.41%
48,000
– –
CMPX icon
11
Compass Therapeutics
CMPX
$369M
$3.06M 2.31%
+872,938
New +$2.76M
PHR icon
12
Phreesia
PHR
$662M
$2.7M 2.04%
114,700
– –
CSTL icon
13
Castle Biosciences
CSTL
$733M
$2.52M 1.9%
110,600
– –
GPCR icon
14
Structure Therapeutics
GPCR
$3.45B
$2.18M 1.65%
78,000
+42,000
+117% +$837K
BDSX icon
15
Biodesix
BDSX
$209M
$2.17M 1.63%
286,804
-2
-0% -$15
QDEL icon
16
QuidelOrtho
QDEL
$1.19B
$2.14M 1.61%
72,548
– –
AXGN icon
17
Axogen
AXGN
$2.12B
$2.12M 1.6%
119,078
-41,922
-26% -$608K
FOLD
18
DELISTED
Amicus Therapeutics
FOLD
$1.99M 1.51%
253,000
+225,000
+804% +$1.6M
HROW icon
19
Harrow
HROW
$1.74B
$1.93M 1.46%
40,000
-20,000
-33% -$753K
EQT icon
20
EQT Corp
EQT
$31B
$1.88M 1.42%
34,619
– –
SLDB icon
21
Solid Biosciences
SLDB
$858M
$1.83M 1.38%
296,955
+118,187
+66% +$691K
OLMA icon
22
Olema Pharmaceuticals
OLMA
$1B
$1.7M 1.29%
174,000
+40,000
+30% +$240K
CYTK icon
23
Cytokinetics
CYTK
$10.9B
$1.65M 1.24%
30,000
+20,000
+200% +$824K
ALKS icon
24
Alkermes
ALKS
$8.79B
$1.5M 1.13%
50,000
– –
FHTX icon
25
Foghorn Therapeutics
FHTX
$305M
$1.38M 1.04%
281,730
-29,200
-9% -$155K
1
2 3 4

Similar funds

RWA
Resolute Wealth Advisor Findlay, Ohio $176M AUM
BAM
Boyar Asset Management New York $176M AUM 20.04% 1-Year Est. Return
TIM
Tevis Investment Management Plano, Texas $176M AUM 18.14% 1-Year Est. Return
TFCM
Taylor Frigon Capital Management Scottsdale, Arizona $176M AUM 24.25% 1-Year Est. Return
FPW
Flywheel Private Wealth Los Altos, California $176M AUM 26.12% 1-Year Est. Return
LWM
Lifetime Wealth Management Rockwall, Texas $176M AUM
PFA
Providence Financial Advisors Overland Park, Kansas $175M AUM
DAM
Draper Asset Management Smithtown, New York $176M AUM 37.45% 1-Year Est. Return

Birchview Capital's Q3 2025 Portfolio in Review

As of Q3 2025, Birchview Capital held 79 positions worth $132M, up 32% from $101M the previous quarter. Its ten largest holdings account for 56% of the portfolio.

Birchview Capital deployed $10.8M of net new capital in Q3 2025, opening 8 new positions and adding to 18 existing holdings. Its largest new stake was Compass Therapeutics: 872,938 shares worth $3.06M.

By sector, the portfolio is most concentrated in Healthcare at 77% of assets, down from 79% a quarter earlier, followed by Technology and Energy.

On the sell side, the largest reduction was Travere Therapeutics, an estimated $1.13M trimmed.

  • Birchview Capital's largest Q3 2025 buy was Compass Therapeutics: 872,938 shares worth $3.06M.
  • Birchview Capital added most to KLA in Q3 2025, an estimated $5.63M increase.
  • Birchview Capital's biggest Q3 2025 reduction was Travere Therapeutics, cutting an estimated $1.13M.
  • Birchview Capital fully exited Xencor in Q3 2025, selling an estimated $550K.
  • Birchview Capital's ten largest holdings make up 56% of its $132M portfolio in Q3 2025.
  • Birchview Capital opened 8 new positions and closed 10 in Q3 2025.
  • Birchview Capital's portfolio value rose 32% quarter-over-quarter to $132M.

Based on Birchview Capital's 13F filing for Q3 2025, filed 13 Nov 2025.